DYNC1I2

Across TCGA pan-cancer cohorts, DYNC1I2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DYNC1I2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DYNC1I2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DYNC1I2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, UCEC, and HNSC are the cancer types where DYNC1I2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.731	0.939	.029	13	view →
UCEC	OS	Median	III,IV	0.433	1.000	.007	12	view →
HNSC	DFS	Quartile	III,IV	0.904	0.620	.015	3	view →
GBM	DFS	Median	All	0.566	0.785	.029	3	view →
PDAC	DFS	Median	III,IV	0.426	0.835	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DYNC1I2–LUAD (DFS)

Open the LUAD breakdown →